Barriers and facilitators to combined ART initiation in pregnant women with HIV: Lessons learnt from a PMTCT B+ pilot program in Swaziland

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue 1, 2015, Pages e24-e30

  Parker, Lucy A ^a   Jobanputra, Kiran ^a   Okello, Velephi ^b   Nhlangamandla, Mpumelelo ^a   Mazibuko, Sikhathele ^b   Kourline, Tatiana ^a   Kerschberger, Bernhard ^a   Pavlopoulos, Elias ^a   Teck, Roger ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b Government of the Kingdom of Eswatini   (Swaziland)

Author keywords

antiretroviral therapy; PMTCT; pregnancy; prevention

Indexed keywords

NEVIRAPINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HEALTH CARE FACILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PILOT STUDY; PREGNANT WOMAN; PRENATAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SWAZILAND; ADOLESCENT; HIV INFECTIONS; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; SWAZILAND; YOUNG ADULT;

EID: 84928426027     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000537     Document Type: Article

References (21)

1. Siegfried N, van der Merwe L, Brocklehurst P, et al. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011:CD003510.
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
3. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359:1178-1186.
4. WHO. Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. WHO, ed. Geneva, Switzerland; 2012.
5. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
6. Hargrove JW, Humphrey JH. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS. 2010;24:F11-F14. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20095074. Accessed March 16, 2014.
7. Schouten EJ, Jahn A, Midiani D, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet. 2011;378:282-284.
8. Strategic information Department, Swaziland Ministry of Health. PMTCT Programme Annual Report 2012. Mbabane, Swaziland; 2013.
9. Mthethwa N. Swaziland paediatric HIV program overview. Paper presented at: National Paediatric HIV Stakeholders Conference; Mbabane, August 6, 2013.
10. Strategic information Department, Swaziland Ministry of Health. PMTCT Programme Annual Report 2011. Mbabane, Swaziland; 2012.
11. Kourline T. Initiation sous traitement antirétroviral des femmes enceintes et allaitantes: Le rôle du personnel soignant et des partenaires. Expérience d'une étude pilote PTME B+ au Swaziland. Poster presented at: AfraVIH; 2014; Montpellier, France.
12. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. World Health Organisation, Geneva, 2013.
13. Swaziland Ministry of Health. Swaziland HIV Incidence Measurement Survey (SHIMS). First Findings Report. Mbabane, Swaziland; 2012.
14. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. World Health Organisation, Geneva, 2010.
15. Gourlay A, Birdthistle I, Mburu G, et al. Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother-to-child transmission of HIV in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2013;16:1-21.
16. Ministry of Health, Government of Malawi. Integrated HIV Program Report July-September 2012. 2012.
17. Tenthani L, Haas AD, Tweya H, et al. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi. AIDS. 2014;28:589-598.
18. Abaynew Y, Deribew A, Deribe K. Factors associated with late presentation to HIV/AIDS care in South Wollo ZoneEthiopia: a casecontrol study. AIDS Res Ther. 2011;8:8.
19. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS. 2012;26:2059-2067.
20. Peltzer K, Pengpid S. Socioeconomic factors in adherence to HIV therapy in low- and middle-income countries. J Health Popul Nutr. 2013; 31:150-170.
21. Cherutich P, Kaiser R, Galbraith J, et al. Lack of knowledge of HIV status a major barrier to HIV prevention, care and treatment efforts in Kenya: results from a nationally representative study. PLoS One. 2012;7:e36797.